Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 13 August, 2007

AIM

Schedule 1 -Omega Diagnostics

AIM
13 August 2007


    ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR
                                                COMPANIES ('AIM RULES')

COMPANY NAME:
Omega Diagnostics Group plc


COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :
Registered Address:

One London Wall, London EC2Y 5AB



Trading Address:

Omega House, Hillfoots Business Village, Alva, Scotland, FK12 5DQ


COUNTRY OF INCORPORATION:
England & Wales


COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:
www.omegadiagnostics.com


COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING STRATEGY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE
STATED:
Admission is sought as a result of a reverse take-over under Rule 14.  Omega has conditionally agreed to acquire the
entire issued share capital of Genesis Diagnostics Limited and Cambridge Nutritional Sciences Limited (together '
Genesis-CNS').



Omega is an established business in the medical diagnostics industry which produces and sells a wide range of
immunoassay and infectious disease IVD test kits and other products through a distribution network in more than 100
countries worldwide. Omega operates in a niche market, supplying tests for specific infectious diseases and other
clinical conditions. The infectious diseases addressed by Omega's products include Syphilis, Tuberculosis, Dengue
Fever, Chagas Disease and Malaria. All products are designed for use in clinical laboratories and Rapid Tests are
designed for use at the point of care. Omega currently exports over 95 per cent. of its products.



Genesis-CNS is a growing, profitable, cash-generative business serving the clinical diagnostics market.  Genesis-CNS
supplies test kits to hospital laboratories in the UK and overseas, via a network of distributors, in 27 countries.
Genesis-CNS produces 80 different test kits, plus a line of 24 quality control products, mainly in the areas of
autoimmune diseases and food intolerance as well as providing testing services for food intolerance and some diseases.



The Enlarged Group's main country of operation will be the UK although it will have a distribution network of more than
100 countries worldwide.


DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known,
number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held
as treasury shares):
14,875,693 New Ordinary Shares of 4p each including 7,333,333 Placing Shares at the Placing Price of 30p per share


CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
Capital to be raised on Admission - £2,200,000

Expected Market Capitalisation on Admission -  £4,462,708


PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:
68.7%


DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE
OR WILL BE ADMITTED OR TRADED:
None


FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or
including any other name by which each is known):
Directors

David Eric Evans (Non-Executive Chairman)

Andrew William Shepherd (Chief Executive Officer)

Kieron Antony Harbinson (Finance Director)

Michael Stephen Gurner (Non-Executive Director)



Proposed Director

Michael Strachan Walker (Non-Executive Director)


FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND
AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

                                        Holding of Existing Ordinary   Holding of New Ordinary Shares of
                                        Shares of 1p each before       4p each after Admission
                                        Admission (as at 3 August
                                        2007)
Michael Strachan Walker*                0%                             29.99%
Kaupthing Singer & Friedlander Group    0%                             13.96%
Brewin Dolphin Securities               0%                             12.10%
Williams de Broe                        0%                             8.07%
Andrew William Shepherd                 26.05%                         6.06%
New Star Asset Management               0%                             5.60%
Scottish Enterprise                     14.71%                         3.05%
Julie Anne Monks Shepherd               7.15%                          1.48%



* shares held through ECS International Trustees (Gibraltar) Ltd


NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:
None


(i)                  ANTICIPATED ACCOUNTING REFERENCE DATE

(ii)                DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED

(iii)               DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:
(i) 31 March

(ii) For Omega 31 March 2007, for Genesis and CNS 31 October 2006

(iii) December 31 2007, September 30 2008 and December 31 2008



N.B.  unaudited results for the 8 months to 30 June 2007 for Genesis and CNS to be announced on 31 August 2007


EXPECTED ADMISSION DATE:
First Admission Date - 31 August 2007
Second Admission Date - 3 September 2007


NAME AND ADDRESS OF NOMINATED ADVISER:
Landsbanki Securities (UK) Limited

Beaufort House

St. Botolph Street

London EC3A 7QR


NAME AND ADDRESS OF BROKER:
Landsbanki Securities (UK) Limited

Beaufort House

St. Botolph Street

London EC3A 7QR


OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL
BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS
SECURITIES:
Copies of the Admission Document are available from www.omegadiagnostics.com



The Admission Document will contain full details about Omega Diagnostics Group PLC and the Admission of it securities
to AIM.
DATE OF NOTIFICATION:
13 August 2007


NEW/ UPDATE:
NEW




                      This information is provided by RNS
            The company news service from the London Stock Exchange